Sony acquires flow cytometry maker iCyt
This article was originally published in The Gray Sheet
Executive Summary
Sony Corp. enters the flow cytometry business through the acquisition of iCyt Mission Technology, a Champaign, Ill., producer of flow cytometers and high-performance cell sorters used for stem cell and disease research, firms announce Feb. 9. Sony has been exploring health care applications for its consumer-based optic technologies, and through the acquisition expects to accelerate development of next-generation cell analysis systems. iCyt founder and CEO Gary Durack will continue to lead iCyt as a wholly-owned subsidiary of Sony
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.